Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity

[1] Gao C(2011)Heparin promotes platelet responsiveness by potentiating αIIβ3-mediated outside-in signaling Blood 117 4946-4952

[2] Boylan B(1992)Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocyopenia Thromb Haemost 68 95-96

[3] Fang J(1993)Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia Thromb Haemost 70 374-375

[4] Wilcox DA(2009)Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management Chest 135 1651-1664

[5] Newman DK(2005)The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment Chest 127 9S-20S

[6] Newman PJ(2006)P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents Eur Heart J 27 1010-1012

[7] Amiral J(2009)Comparing the antiplatelet effects of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study Clin Res Cardiol 98 533-540

[8] Bridey F(2009)Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association Clin Res Cardiol 98 1-7

[9] Dreyfus M(2011)Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study Clin Res Cardiol 100 29-36

[10] Vissoc AM(2011)Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation Clin Res Cardiol 100 765-771

[1] Gao C(2011)Heparin promotes platelet responsiveness by potentiating αIIβ3-mediated outside-in signaling Blood 117 4946-4952

[2] Boylan B(1992)Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocyopenia Thromb Haemost 68 95-96

[3] Fang J(1993)Further evidence that alpha-granule components such as platelet factor 4 are involved in platelet-IgG-heparin interactions during heparin-associated thrombocytopenia Thromb Haemost 70 374-375

[4] Wilcox DA(2009)Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management Chest 135 1651-1664

[5] Newman DK(2005)The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment Chest 127 9S-20S

[6] Newman PJ(2006)P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents Eur Heart J 27 1010-1012

[7] Amiral J(2009)Comparing the antiplatelet effects of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study Clin Res Cardiol 98 533-540

[8] Bridey F(2009)Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association Clin Res Cardiol 98 1-7

[9] Dreyfus M(2011)Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study Clin Res Cardiol 100 29-36

[10] Vissoc AM(2011)Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation Clin Res Cardiol 100 765-771